Leadership updates at the AACR signal a continued influence from Penn, with Robert Vonderheide, MD, DPhil, Director of the Abramson Cancer Center, stepping into the role of AACR President-Elect for the 2026-2027 tenure. Concurrently, E. John Wherry, PhD, a distinguished professor and department chair at Penn, joins the AACR Board of Directors. Their leadership will steer the organization’s scientific agenda towards enhanced collaboration and translational research, bridging preclinical discoveries and clinical application. These appointments reflect the deep engagement of Penn researchers in national and international cancer science leadership and policy-making.

One of the hallmark presentations poised to attract intense interest is the Opening Plenary Session featuring Carl June, MD, a pioneer in CAR T cell therapy. June will detail significant advances in extending CAR T therapy from hematological malignancies into the more challenging arena of solid tumors. This includes novel “armored” CAR T cells capable of resisting the hostile tumor microenvironment, as well as dual-target engineered CARs designed specifically to confront glioblastoma, a notably aggressive brain cancer. The technical complexity of these next-generation cellular therapies lies in enhancing persistence, efficacy, and tumor specificity while mitigating off-target effects and immune-related toxicities.

Further into the meeting, riveting clinical data will be disclosed from the STAR-101 Phase 1 Clinical Trial, a pioneering study investigating KIR-CAR T cells in patients who have advanced mesothelin-expressing solid tumors such as ovarian cancer and cholangiocarcinoma. Unlike conventional CAR T cells, these KIR-CARs leverage natural killer (NK) cell receptors to overcome T cell exhaustion—a major limitation in prolonged immunotherapy efficacy. The multi-chain receptor design introduces a new dimension in immune engineering, aiming to reinvigorate anti-tumor responses in difficult-to-treat solid malignancies. Janos L. Tanyi, MD, PhD, the study’s principal investigator, will be sharing these initial clinical outcomes, which bear significant implications for durable cancer control.

On the front of early interception and prevention strategies, Minh Than, MD, PhD, will discuss innovative work illustrating how targeting active RAS signaling pathways can prevent pancreatic cancer development at its nascent stages in murine models. These findings represent a monumental shift from treatment paradigms to cancer interception, emphasizing the eradication of precancerous lesions before tumorigenesis. The utilization of genetically engineered mice to mimic human pancreatic cancer evolution offers mechanistic insights into the molecular drivers of oncogenesis and potential intervention points.

Cancer immunotherapy remains a dominant theme, with E. John Wherry chairing a symposium dedicated to immune evasion mechanisms and immune dysregulation in malignancies. Specifically, Wherry will elaborate on the pharmacodynamics of anti-PD-1 therapies and their capacity to reinvigorate exhausted CD8+ T cells within the tumor microenvironment. Understanding T cell exhaustion—characterized by diminished effector function and sustained expression of inhibitory receptors—is pivotal for refining checkpoint blockade strategies and improving therapeutic durability.

Integrating artificial intelligence (AI) into oncology diagnostics also figures prominently in Penn’s presentations. Mingyao Li, PhD’s work on AI-powered tissue mapping melds spatial transcriptomics with histopathology images to generate detailed molecular and cellular maps within tumors. This fusion of computational pathology and spatial omics facilitates a granular understanding of tumor heterogeneity, microenvironmental interactions, and disease progression. The promise of predictive AI models extends to prognosis, treatment response assessment, and personalized therapy design.

Saar Gill, MD, PhD, will contribute vital knowledge to emerging methodologies for in vivo CAR T cell generation. The current ex vivo manufacturing process is complex, labor-intensive, and costly. Gill’s research envisions technologies that could directly engineer CAR T cells within the patient’s body, bypassing extensive laboratory manipulation. The feasibility of in vivo gene editing and delivery mechanisms is a cutting-edge development potentially revolutionizing cell-based immunotherapies by enhancing accessibility and scalability.

In cervical cancer prevention, Carmen Guerra, MD, is advancing community-level interventions through HPV self-sampling approaches, crucial for early detection and screening in underserviced populations. Chairing a session on vaccination and self-sampling, Guerra’s work leverages community outreach to address significant disparities in cervical cancer outcomes globally. These public health strategies demonstrate how molecular diagnostics can be translated beyond the lab bench into impactful epidemiological interventions.

Recognition of early-stage investigators is exemplified by Carman Man-Chung Li, PhD receiving the AACR Gertrude B. Elion Cancer Research Award. Li’s research delves into the chromatin priming mechanisms that underpin the initiation and aggressiveness of basal-like breast cancer. Epigenetic alterations driving tumor heterogeneity and plasticity are emerging as promising targets for interception therapies that aim to halt cancer progression at its earliest chromatin-based regulatory events.

Adding to the momentum, Amulya Sreekumar, PhD, featured as an AACR NextGen Star, highlights the role of residual breast cancer cells in endogenous dormancy, maintained via SOX5-driven endochondral ossification pathways. This novel mechanistic insight into tumor cell dormancy after conventional therapy is vital for developing therapeutic regimens aimed at eradicating minimal residual disease and preventing relapse. The translational value is underscored by ongoing clinical trials targeting disseminated tumor cells, led by Lewis Chodosh, MD, PhD.

Penn Medicine continues to serve as a crucible for transformative discoveries, wielding a multidisciplinary approach that synergizes clinical expertise, molecular biology, immunology, bioinformatics, and community health. This AACR Annual Meeting highlights not only the technological and therapeutic strides but also the comprehensive ecosystems required to accelerate innovation from bench to bedside. As cancer therapy enters a new era defined by precision and immunologic sophistication, the University of Pennsylvania stands at the vanguard, shaping the future of oncology for patient benefit worldwide.

For media inquiries and interview arrangements with Penn Medicine experts during the AACR meeting, contact Meagan Raeke at Meagan.Raeke@pennmedicine.upenn.edu or via phone at 267-693-6224.

Subject of Research: Advances in CAR T cell therapies, immune evasion, cancer interception, AI in oncology diagnostics, and cancer prevention strategies.

Article Title: Transforming Oncology: Penn Medicine’s Pioneering Research at AACR Annual Meeting 2026

News Publication Date: April 2026

Web References:

• https://www.aacr.org/meeting/aacr-annual-meeting-2026/
• https://www.pennmedicine.org/Specialties/Cancer/About-Abramson-Cancer-Center
• https://clinicaltrials.gov/study/NCT05568680
• https://www.pennmedicine.org/news/pioneering-strategy-may-keep-breast-cancer-from-coming-back

Keywords: CAR T cell therapy, solid tumors, immunotherapy, cancer prevention, immune evasion, AI pathology, pancreatic cancer, cervical cancer prevention, KIR-CAR, tumor dormancy, basal-like breast cancer, translation research

For decades, oncologists and immunologists have grappled with the challenge of T cell exhaustion, a state wherein T cells, after persistent stimulation by cancer antigens or chronic infections, lose their ability to mount effective anti-tumor responses. Although these exhausted T cells retain recognition of cancer-specific antigens, their cytotoxic activity becomes blunted, allowing tumors to progress unchecked. The immune checkpoint protein PD1 has long been implicated in this process, with therapies aimed at inhibiting PD1 reviving T cell activity and yielding impressive clinical results in cancers such as melanoma. However, resistance and diminishing responses in a substantial subset of patients have driven researchers to probe deeper into the molecular brakes that tumors use, seeking alternative or complementary targets.

The team led by Dr. Taha Merghoub and Dr. Jedd Wolchok sought to explore whether CD47, a surface molecule with known “don’t eat me” functions that protect cancer cells from macrophage-mediated destruction, plays a role in T cell exhaustion. Notably, their investigations revealed a transformative insight: CD47 is not just expressed on tumor cells but is also upregulated on T cells themselves, especially in their exhausted state. This unexpected discovery pointed to CD47 functioning as an intrinsic checkpoint in T cells, where its increased expression correlates with diminished immune surveillance and tumor control.

Through rigorous in vivo modeling, the researchers demonstrated that mice genetically deficient in CD47 experienced delayed tumor development, implicating CD47 expression on immune cells as a factor driving immune suppression. More intriguingly, T cells devoid of CD47 showed enhanced tumor-fighting abilities compared to their CD47-expressing counterparts, providing compelling experimental evidence that CD47 acts as an exhaustion facilitator within T cells. This revelation challenges the conventional paradigm that primarily considered CD47 as a shield for cancer cells and expands its functional repertoire into immune regulation.

Delving further, the scientists examined how the tumor microenvironment may exploit this newfound T cell CD47 pathway. They identified thrombospondin-1 (TSP-1), a large matricellular protein frequently secreted by metastatic tumors, as a critical ligand that binds CD47. Mice lacking thrombospondin-1 similarly exhibited reduced T cell exhaustion, validating the role of the CD47-TSP-1 interaction in promoting immune cell dysfunction. This finding was a pivotal moment in the research—establishing the TSP-1:CD47 molecular axis as a key modulator of T cell vitality within tumors.

To translate this mechanistic understanding into therapeutic potential, the team employed the TAX2 peptide, a selective inhibitor designed to disrupt the binding between TSP-1 and CD47. Treatment of mouse models bearing melanoma and colorectal tumors with TAX2 resulted in preserved T cell function, enhanced cytokine production, increased tumor infiltration by immune cells, and ultimately, significantly slowed tumor growth. These data represent an encouraging proof-of-concept that targeting the TSP-1:CD47 pathway can reverse T cell exhaustion and invigorate anti-tumor immunity.

Perhaps most strikingly, the study also revealed that TAX2 acts synergistically with PD-1 blockade therapies, amplifying T cell reactivation and improving tumor control beyond what either intervention could achieve alone. This synergy underscores the potential for combination immunotherapies focusing on multiple exhaustion pathways to overcome resistance and sustain durable anticancer immune responses. Based on these promising preclinical results, Dr. Merghoub and his colleagues envision expanding their research to identify upstream and downstream regulators of the TSP-1:CD47 signaling axis, aiming to develop targeted therapeutics capable of safely and effectively modulating this pathway in human patients.

The implications of this research are far-reaching. By exposing a novel mechanism employed by tumors to subvert the immune system, it opens avenues for next-generation immunotherapies that enhance T cell persistence and functionality. Since T cell exhaustion represents a significant obstacle limiting the success of current immune checkpoint inhibitors, therapies disrupting the CD47-TSP-1 interaction could become instrumental in extending benefits to a wider patient population. Moreover, the dual blockade of PD1 and CD47 pathways may offer a powerful strategy to counteract tumor immune evasion, potentially transforming clinical cancer management.

This study exemplifies the synergy of basic molecular immunology with translational cancer research. It showcases how dissecting complex cellular interactions at the protein signaling level can reveal unexpected therapeutic targets, shifting the paradigm from solely targeting tumor cells to also manipulating immune cell phenotypes. The hope is that, with continued investigation and clinical development, interventions based on these findings will provide durable, efficient, and broadly applicable cancer immunotherapies, ultimately harnessing the immune system’s full power to defeat tumors.

As the scientific community progresses in understanding tumor-driven immune suppression, the CD47-TSP-1 discovery shines as a beacon guiding future efforts. By selectively severing this pathological crosstalk, researchers aim not only to halt tumor progression but also to restore the immune system’s intrinsic capacity to eliminate cancer. With ongoing preclinical and forthcoming clinical studies, the vision of revitalized and resilient T cells growing ever closer portends a hopeful era in oncology.

Subject of Research: Molecular mechanisms of T cell exhaustion and tumor immune evasion

Article Title: Tumors exploit the CD47-Thrombospondin-1 axis to induce T cell exhaustion and immune escape

News Publication Date: 17-Nov-2025

Web References: https://www.nature.com/articles/s41590-025-02321-5

Keywords: T cell exhaustion, CD47, thrombospondin-1, immunotherapy, immune checkpoint, PD1, cancer immunology, tumor microenvironment, melanoma, colorectal cancer, immune evasion, immune reprogramming

T cell plasticity is a central theme in the immune response against tumors, and modulating specific cytokine receptor pathways is an attractive avenue to harness this plasticity therapeutically. The new approach taken by the research team involves constructing an orthogonal signaling system whereby the IL-4 receptor is engineered to respond exclusively to a modified IL-2 cytokine, dubbed human orthogonal IL-2 (hoIL-2). The chimeric receptor, ho4R, essentially couples IL-2 engagement with IL-4 receptor signaling cascades, fueling T cell differentiation programs associated with type 2 cytokine production, including IL-4, IL-5, and IL-13.

To interrogate the functional consequences of this synthetic cytokine receptor architecture, human T cells were genetically modified to express the ho4R fused with a defined T cell receptor (TCR) specific for the melanoma-associated antigen NY-ESO-1 presented by HLA*0201. When cultured with the engineered cytokine MSA–hoIL-2, the ho4R-expressing TCR-T cells showed a pronounced enrichment of T helper 2 (T_H2) and cytotoxic T type 2 (T_C2) cells. This shift was marked by significant increases in intracellular production of hallmark type 2 cytokines, with IL-4+, IL-5+, and IL-13+ subpopulations markedly expanded among both CD4+ and CD8+ T cell compartments when compared to non-transduced controls.

One striking feature of this engineered signaling was its capacity to promote hybrid phenotypes co-expressing IFNγ alongside type 2 cytokines. This dual cytokine expression challenges the traditional dogma of rigid and mutually exclusive T cell polarization, highlighting a versatile and potentially more effective effector profile. Moreover, flow cytometric analyses revealed that the transcription factor GATA3, a master regulator of type 2 differentiation, was substantially upregulated in ho4R-modified cells, alongside elevated CCR4 expression, affirming the genuine induction of a type 2 molecular program.

These in vitro phenotypic changes translated into significant therapeutic impact in vivo. Administering the ho4R-engineered NY-ESO-1 TCR-T cells into immunodeficient NSG mice bearing subcutaneous melanoma tumors yielded profound tumor suppression compared to treatment with conventional TCR-T cells. Simultaneous systemic delivery of MSA–hoIL-2 ensured selective activation of the orthogonal receptor signaling axis, enhancing the persistence and functionality of the engineered T cells in the hostile tumor microenvironment.

Further in vivo analyses underscored the durability of type 2 differentiation prompted by ho4R signaling. Spleen-resident T cells from treated mice demonstrated remarkably elevated frequencies of IL-4+, IL-5+, and IL-13+ subsets without measurable systemic toxicity or weight loss, an important consideration for clinical translation. This confirms that synthetic cytokine receptor-ligand pairs can establish new immunological niches conducive to tumor control while maintaining an acceptable safety profile.

Mechanistically, the indispensability of GATA3 in mediating the antitumor efficacy of ho4R T cells was conclusively demonstrated by CRISPR/Cas9-dependent knockout experiments. Loss of GATA3 completely abolished the therapeutic benefits, indicating that the engineered IL-4 receptor signaling operates through canonical transcriptional regulators to effectuate sustained type 2 programs necessary for immune-mediated tumor destruction.

Importantly, blocking one or multiple type 2 cytokines in vitro did not impair the antitumor functionality, implying either redundancy or compensatory mechanisms within the cytokine network elicited by this synthetic signaling. This highlights an advantage of orthogonal receptor systems in activating complex cellular programs which may be resilient to single-cytokine interruptions, potentially overcoming resistance mechanisms observed in conventional immunotherapies.

This research heralds a new frontier wherein the cytokine receptor alphabet can be expanded and rewired to empower T cells with bespoke functional states tailored for specific therapeutic applications. By decoupling receptor activation from endogenous ligands and creating orthogonally selective cytokine-receptor pairs, scientists have unlocked nuanced control over immune cell fate decisions.

The implications of this approach extend beyond cancer. The ability to engineer T cell polarization with high precision offers prospects for improved treatments of autoimmune diseases, allergies, and infectious diseases, where fine-tuning immune responses is critical. The modular nature of chimeric cytokine receptors also opens avenues to design synthetic immune circuits responsive to customized inputs, pushing the boundaries of synthetic immunology.

Moreover, the demonstrated efficacy of ho4R signaling in concert with orthogonal IL-2 agonists establishes a platform for safer, more controllable adoptive cell transfer therapies. This could greatly reduce systemic toxicities and cytokine release syndromes by restricting potent cytokine stimulation to engineered cells expressing matching orthogonal receptors.

This advance underscores the importance of synthetic biology tools in immunoengineering, moving beyond simple receptor overexpression to complex reprogramming of intracellular signaling networks. Future studies will undoubtedly explore combinatorial cytokine receptor designs to generate multifunctional T cells capable of adapting dynamically to tumor microenvironments and overcoming diverse immunosuppressive barriers.

As the field moves forward, integrating orthogonal cytokine receptor systems with genomic editing and high-dimensional phenotyping will refine the potency, stability, and safety of engineered T cells. Such approaches may eventually culminate in off-the-shelf cellular therapies with tunable effector profiles optimized for individual patient tumors.

In conclusion, this study leverages synthetic cytokine receptor engineering to successfully rewire T cell fate decisions and amplify anti-cancer immunity. By introducing a human orthogonal IL-4 receptor and its cognate ligand, researchers have created a robust framework for generating durable type 2 T cell responses with enhanced therapeutic efficacy. This innovative platform holds the potential to reshape adoptive T cell therapies across oncology and beyond, providing a compelling blueprint for the next generation of precision immunotherapy.

Subject of Research: Engineering T cells with human orthogonal chimeric IL-4 receptor signaling to induce type 2 differentiation and enhance anti-tumor activity in melanoma models.

Article Title: Expanding the cytokine receptor alphabet reprograms T cells into diverse states.

Article References:
Zhao, Y., Ogishi, M., Pal, A. et al. Expanding the cytokine receptor alphabet reprograms T cells into diverse states. Nature (2025). https://doi.org/10.1038/s41586-025-09393-1

Image Credits: AI Generated

Current oncological care models, largely designed for more traditional treatment modalities, are ill-equipped to handle the multifaceted demands imposed by precision medicine and immunotherapies. Targeted therapies exploit specific genetic and molecular aberrations within tumor cells, necessitating sophisticated diagnostic and monitoring protocols. Similarly, immunotherapies—therapies that activate a patient’s immune system to attack cancer cells—introduce unique toxicity profiles and require frequent clinical assessments to manage adverse events effectively. Consequently, patients undergoing these treatments face an increased frequency of clinical visits, and healthcare providers are confronted with intensified demands on their time and expertise.

A pivotal example lies in melanoma treatment, where immunotherapy has elevated 10-year survival rates to over 50%, marking a remarkable shift from historically dismal prognoses. However, such improved outcomes have a dual effect: while heralding hope, they generate a longitudinal care challenge, as survivors require prolonged monitoring and management of therapy-related complications. This paradigm shift underscores the urgent necessity to rethink workforce capacity and care delivery models in oncology.

Key challenges include a shortage of oncologists relative to the rising patient loads and the elevated complexity of care. Increasing the number of oncology specialists via expanded medical school enrollment and incentivizing oncology training pathways represent initial steps but may be insufficient on their own due to the lengthy training timeframes. To address these challenges effectively, there is a growing consensus on embracing multidisciplinary, team-based care frameworks that leverage the skills of general practice oncologists (GPOs), nurse practitioners, physician assistants, oncology nurses, and clinical pharmacists trained specifically in oncology.

This coordinated model redistributes clinical responsibilities, allowing specialists to focus on complex decision-making while adjunct health professionals manage routine follow-ups and symptom control. Enhancing the oncology expertise among these allied professionals through targeted training programs is paramount for maintaining high standards of care. Such infrastructural growth mitigates workforce bottlenecks and aligns with contemporary patient-centered care principles.

Resource optimization is equally critical. The burgeoning availability of expensive and complex therapies mandates judicious allocation to maximize clinical benefit while minimizing unnecessary interventions. The prevailing norms of routine surveillance through diagnostic imaging and frequent hospital visits for asymptomatic patients require re-evaluation. Emerging evidence suggests that indiscriminate post-treatment surveillance may not improve patient outcomes and often leads to excessive healthcare spending, patient inconvenience, and potential exposure to radiation or invasive procedures without proportional benefits.

Indeed, an evidence-based approach to follow-up care, grounded in rigorous risk-benefit assessments, is essential. Reducing the frequency of routine assessments absent clear clinical indications can alleviate system strain and lessen patient burden. This practice shift demands consensus guidelines supported by high-quality data and tailored to the evolving landscape of cancer survivorship.

Operationalizing these solutions involves complex systemic changes across many levels of Canadian healthcare. Policy makers, hospital administrators, and healthcare providers must collaborate to develop and fund innovative care models that are scalable and sustainable. Investments in interdisciplinary specialty clinics, where collaborative teams provide integrated care, are especially promising. These clinics enhance communication, streamline patient pathways, and foster a holistic approach to cancer management.

Dr. Andreas Laupacis, a prominent voice in healthcare policy, emphasizes the broader physician shortage crisis affecting disciplines beyond oncology. His editorial advocates for similarly structured interdisciplinary clinics across various specialties to ensure high-quality, accessible care nationwide. Establishing optimal funding models for these initiatives is essential to realize their potential benefits fully.

A fundamental cultural shift in oncology care delivery is on the horizon, recognizing that survival alone is no longer the sole outcome of interest. The focus expands to encompass quality of life, functional status, and minimizing the long-term sequelae of treatment. This evolution places new demands on clinicians, requiring enhanced competencies in symptom management, psychosocial support, and coordination with primary care and rehabilitation services.

Ultimately, the future of cancer care in Canada hinges on proactive adaptation to the oncology workforce crisis. Ensuring that advances in therapy translate into tangible benefits for all patients demands structural transformations that prioritize teamwork, training, data-driven practice, and resource stewardship. Without such changes, the promise of modern oncology innovations risks being compromised by systemic shortcomings.

As the number of cancer survivors grows, so too does the imperative to safeguard their comprehensive well-being. The next decade will likely witness the integration of multidisciplinary care models that blend cutting-edge scientific discovery with pragmatic healthcare delivery strategies. Stakeholders must act promptly to secure a resilient oncology workforce capable of meeting Canada’s evolving cancer care landscape.

The challenges are formidable but surmountable through coordinated efforts encompassing education, policy reform, clinical innovation, and patient engagement. A reimagined oncology workforce, equipped with diverse expertise and supported by robust infrastructure, offers the best pathway to fulfilling the promise of modern cancer therapy—prolonged survival with preserved quality of life across the continuum of care.

Subject of Research: People

Article Title: Advances in cancer therapy require urgent changes to the oncology workforce

News Publication Date: 2-Jun-2025

Web References:
https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241425

References:

• Walker J, et al. Advances in cancer therapy require urgent changes to the oncology workforce. CMAJ. 2025; PMID and DOI available online.
• Laupacis A. Editorial on interdisciplinary specialty care clinics. CMAJ. 2025.

Keywords: Cancer; Cancer immunology; Oncology; Medical treatments; Clinical medicine